{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:44:59Z","timestamp":1788637499676,"version":"build-2803163510"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100003341","name":"Sarcoma Foundation of America","doi-asserted-by":"publisher","award":["222433"],"award-info":[{"award-number":["222433"]}],"id":[{"id":"10.13039\/100003341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA151452-01"],"award-info":[{"award-number":["CA151452-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UO1"],"award-info":[{"award-number":["UO1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ctrv.2019.101934","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T11:28:50Z","timestamp":1574681330000},"page":"101934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications"],"prefix":"10.1016","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6965-9354","authenticated-orcid":false,"given":"Pichaya","family":"Thanindratarn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan C.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8435-5065","authenticated-orcid":false,"given":"Scott D.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Hornicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7276-3910","authenticated-orcid":false,"given":"Zhenfeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2019.101934_b0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ctrv.2019.101934_b0010","unstructured":"Noone AM HN, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015. National Cancer Institute Bethesda, MD, https:\/\/seercancergov\/csr\/1975_2015\/. 2018."},{"key":"10.1016\/j.ctrv.2019.101934_b0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","article-title":"The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial","volume":"109","author":"Pasquali","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2019.101934_b0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaoncol.2017.4996","article-title":"Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: the EORTC 62961-ESHO 95 randomized clinical trial","volume":"4","author":"Issels","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0025","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0030","first-page":"iv79-iv95","article-title":"Bone sarcomas: ESMO-PaedCan-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010170","article-title":"Therapeutic targets for bone and soft-tissue sarcomas","volume":"20","author":"Miwa","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2019.101934_b0040","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2008.21.3223","volume":"27","author":"Sleijfer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0045","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2019.101934_b0050","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0055","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/annonc\/mds607","article-title":"Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy","volume":"24","author":"Santoro","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1470-2045(18)30742-3","article-title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study","volume":"20","author":"Duffaud","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0065","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101934_b0070","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/mt.2010.313","article-title":"Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0075","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3389\/fimmu.2018.02493","article-title":"Engineering CAR-T cells for improved function against solid tumors","volume":"9","author":"Morgan","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2019.101934_b0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.ctrv.2019.101934_b0085","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3109\/08830185.2015.1018419","article-title":"Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy","volume":"34","author":"Figueroa","year":"2015","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.ctrv.2019.101934_b0090","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2013.11.002","article-title":"The ErbB\/HER family of protein-tyrosine kinases and cancer","volume":"79","author":"Roskoski","year":"2014","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0095","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.molmed.2007.10.002","article-title":"The HER family and cancer: emerging molecular mechanisms and therapeutic targets","volume":"13","author":"Sergina","year":"2007","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ctrv.2019.101934_b0100","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/852748","article-title":"Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Mol Biol Int"},{"key":"10.1016\/j.ctrv.2019.101934_b0105","article-title":"Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma","volume":"59\u201365","author":"Morris","year":"2001","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0110","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0115","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3889\/oamjms.2018.318","article-title":"HER-2 immunohistochemical expression in bone sarcomas: a new hope for osteosarcoma patients","volume":"6","author":"Tabak","year":"2018","journal-title":"Open Access Maced J Med Sci"},{"key":"10.1016\/j.ctrv.2019.101934_b0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.4103\/1947-2714.183013","article-title":"Coexistence of HER2, Ki67, and p53 in osteosarcoma: a strong prognostic factor","volume":"8","author":"Mardanpour","year":"2016","journal-title":"N Am J Med Sci"},{"key":"10.1016\/j.ctrv.2019.101934_b0125","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/hed.20267","article-title":"C-erb-B2 (HER2\/neu) expression in synovial sarcoma of the head and neck","volume":"27","author":"Olsen","year":"2005","journal-title":"Head Neck"},{"key":"10.1016\/j.ctrv.2019.101934_b0130","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.ejca.2005.03.015","article-title":"Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma","volume":"41","author":"Scotlandi","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2019.101934_b0135","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1200\/JCO.1999.17.9.2781","article-title":"Expression of HER2\/erbB-2 correlates with survival in osteosarcoma","volume":"17","author":"Gorlick","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0140","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/PAI.0000000000000197","article-title":"The prognostic role of Ezrin and HER2\/neu expression in osteosarcoma","volume":"24","author":"Abdou","year":"2016","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ctrv.2019.101934_b0145","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1200\/JCO.2011.37.4546","article-title":"Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children's oncology group","volume":"30","author":"Ebb","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0150","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0155","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0160","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/cgt.2011.83","article-title":"Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma","volume":"19","author":"Rainusso","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0165","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/pbc.26097","article-title":"Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults","volume":"63","author":"Dobrenkov","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ctrv.2019.101934_b0170","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2174\/156800910791054167","article-title":"Anti-GD2 antibody therapy for GD2-expressing tumors","volume":"10","author":"Navid","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ctrv.2019.101934_b0175","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.101934_b0180","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","article-title":"Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas","volume":"4","author":"Long","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0185","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2016.01.004","article-title":"The role of IL-11 in immunity and cancer","volume":"373","author":"Xu","year":"2016","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2019.101934_b0190","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/0008-5472.CAN-08-4845","article-title":"The interleukin-11 receptor alpha as a candidate ligand-directed target in osteosarcoma: consistent data from cell lines, orthotopic models, and human tumor samples","volume":"69","author":"Lewis","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0195","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1002\/jcb.24211","article-title":"Interleukin-11 increases cell motility and up-regulates intercellular adhesion molecule-1 expression in human chondrosarcoma cells","volume":"113","author":"Li","year":"2012","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ctrv.2019.101934_b0200","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s13277-014-2844-6","article-title":"Interleukin-11 receptor alpha is overexpressed in human osteosarcoma, and near-infrared-labeled IL-11Ralpha imaging agent could detect osteosarcoma in mouse tumor xenografts","volume":"36","author":"Liu","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.ctrv.2019.101934_b0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1158\/0008-5472.CAN-11-2778","article-title":"Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases","volume":"72","author":"Huang","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0210","doi-asserted-by":"crossref","first-page":"2611","DOI":"10.3892\/ol.2017.6497","article-title":"Cancer associated fibroblasts: an essential role in the tumor microenvironment","volume":"14","author":"Tao","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2019.101934_b0215","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1158\/1535-7163.MCT-11-0340","article-title":"Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy","volume":"11","author":"Brennen","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0220","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2019.101934_b0225","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0230","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1158\/1535-7163.MCT-09-0115","article-title":"Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines","volume":"8","author":"Duan","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0235","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","article-title":"R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study","volume":"29","author":"Pappo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0240","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2011.37.4355","article-title":"Phase I\/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the children's oncology group","volume":"30","author":"Malempati","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101934_b0245","article-title":"Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101934_b0250","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/mabs.19870","article-title":"Targeting malignant B cells with an immunotoxin against ROR1","volume":"4","author":"Baskar","year":"2012","journal-title":"MAbs."},{"key":"10.1016\/j.ctrv.2019.101934_b0255","article-title":"ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth","volume":"7","author":"Zhang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101934_b0260","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2019.101934_b0265","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2019.101934_b0270","article-title":"IGF1R- and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101934_b0275","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1158\/1078-0432.CCR-15-2428","article-title":"Molecular pathways: targeting B7\u2013H3 (CD276) for human cancer immunotherapy","volume":"22","author":"Picarda","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0280","article-title":"B7\u2013H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101934_b0285","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2559.2008.03070.x","article-title":"Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7\u2013H3 surface molecule","volume":"53","author":"Gregorio","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2019.101934_b0290","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"CAR T cells targeting B7\u2013H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0295","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc3023","article-title":"CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?","volume":"11","author":"Zoller","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.101934_b0300","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fcell.2018.00097","article-title":"CD44\/CD44v6 a reliable companion in cancer-initiating cell maintenance and tumor progression","volume":"6","author":"Wang","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.ctrv.2019.101934_b0305","doi-asserted-by":"crossref","first-page":"45848","DOI":"10.18632\/oncotarget.17435","article-title":"Regulation of CD44v6 expression in gastric carcinoma by the IL-6\/STAT3 signaling pathway and its clinical significance","volume":"8","author":"Xu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.101934_b0310","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.2147\/OTT.S156101","article-title":"Prognostic value of CD44v6 expression in breast cancer: a meta-analysis","volume":"11","author":"Qiao","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0315","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3892\/or.2013.2273","article-title":"CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer","volume":"29","author":"Saito","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2019.101934_b0320","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.18632\/oncotarget.14163","article-title":"CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.101934_b0325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13018-015-0328-z","article-title":"Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis","volume":"10","author":"Zhang","year":"2015","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0330","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1054\/bjoc.2000.1590","article-title":"The adhesion molecule CD44v6 is associated with a high risk for local recurrence in adult soft tissue sarcomas","volume":"84","author":"Maula","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.101934_b0335","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1423167","article-title":"CD44v6 as innovative sarcoma target for CAR-redirected CIK cells","volume":"7","author":"Leuci","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2019.101934_b0340","first-page":"437","article-title":"The fetal form of the acetylcholine receptor distinguishes rhabdomyosarcomas from other childhood tumors","volume":"152","author":"Gattenloehner","year":"1998","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2019.101934_b0345","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/14728222.2013.734500","article-title":"Targeting the fetal acetylcholine receptor in rhabdomyosarcoma","volume":"17","author":"Simon-Keller","year":"2013","journal-title":"Exp Opin Ther Targets"},{"key":"10.1016\/j.ctrv.2019.101934_b0350","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1158\/0008-5472.CAN-05-0542","article-title":"Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor","volume":"66","author":"Gattenlohner","year":"2006","journal-title":"Cancer Res"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2019.101934_b0355","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00292-010-1344-8","article-title":"Adoptive T-cell therapy of rhabdomyosarcoma","volume":"31","author":"Simon-Keller","year":"2010","journal-title":"Pathologe"},{"key":"10.1016\/j.ctrv.2019.101934_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19010177","article-title":"Fusion Proteins of NKG2D\/NKG2DL in cancer immunotherapy","volume":"19","author":"Ding","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2019.101934_b0365","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.canlet.2015.07.042","article-title":"Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner","volume":"368","author":"Fernandez","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2019.101934_b0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031210","article-title":"Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection","volume":"7","author":"Lehner","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101934_b0375","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.1158\/1078-0432.CCR-17-0075","article-title":"Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells","volume":"23","author":"Fernandez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0380","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2019.101934_b0385","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/modpathol.2012.133","article-title":"The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas","volume":"26","author":"Hemminger","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2019.101934_b0390","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/ijc.1451","article-title":"Monophasic and biphasic synovial sarcomas abundantly express cancer\/testis antigen NY-ESO-1 but not MAGE-A1 or CT7","volume":"94","author":"Jungbluth","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2019.101934_b0395","doi-asserted-by":"crossref","first-page":"3366-","DOI":"10.1182\/blood.V128.22.3366.3366","article-title":"Combination immunotherapy with NY-ESO-1-specific CAR+ T cells with T-cell vaccine improves anti-myeloma effect","volume":"128","author":"Patel","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101934_b0400","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101934_b0405","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2019.101934_b0410","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2013.144","article-title":"Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer","volume":"24","author":"van Schalkwyk","year":"2013","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.1016\/j.ctrv.2019.101934_b0415","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.101934_b0420","doi-asserted-by":"crossref","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2019.101934_b0425","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jocn.2013.03.012","article-title":"Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma","volume":"21","author":"Choi","year":"2014","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ctrv.2019.101934_b0430","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2019.101934_b0435","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","article-title":"Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0440","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0445","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2019.101934_b0450","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1101\/gad.169029.111","article-title":"Immune microenvironments in solid tumors: new targets for therapy","volume":"25","author":"Shiao","year":"2011","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2019.101934_b0455","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1158\/0008-5472.CAN-15-3352","article-title":"TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors","volume":"76","author":"Menger","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0460","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0465","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0470","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0475","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2019.101934_b0480","doi-asserted-by":"crossref","first-page":"10541","DOI":"10.1038\/s41598-017-10940-8","article-title":"Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment","volume":"7","author":"Yeku","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2019.101934_b0485","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0490","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/gt.2013.19","article-title":"Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency","volume":"20","author":"Wang","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0495","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J Immunother"},{"key":"10.1016\/j.ctrv.2019.101934_b0500","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2019.101934_b0505","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","article-title":"A chimeric switch-receptor targeting PD1 augments the efficacy of second-generation CAR T cells in advanced solid tumors","volume":"76","author":"Liu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: significance and effective mechanisms","volume":"322","author":"Davoodzadeh Gholami","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ctrv.2019.101934_b0515","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"10.1016\/j.ctrv.2019.101934_b0520","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082742","article-title":"Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma","volume":"8","author":"Budde","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101934_b0525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14712598.2014.860442","article-title":"CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road","volume":"14","author":"Gill","year":"2014","journal-title":"Exp Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2019.101934_b0530","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/imr.12139","article-title":"Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells","volume":"257","author":"Jensen","year":"2014","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ctrv.2019.101934_b0535","doi-asserted-by":"crossref","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","article-title":"PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses","volume":"5","author":"Fedorov","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2019.101934_b0540","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219301550?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219301550?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:20:16Z","timestamp":1778685616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219301550"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":108,"alternative-id":["S0305737219301550"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101934","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101934"}}